MUC1 and cancer: While the anti-cancer vaccines of MUC1, p53, CpG, and SOX2 have some pre-clinical and clinical efficacy, there is an increasing amount of evidence that points to radiation’s effectiveness as an in situ vaccine that can prime the patient’s immune system against systemic disease.